港股异动 | 开拓药业-B高开近3% LK-1单抗联合NIVOLUMAB治疗晚期肝细胞癌的II期临床试验完成美国首例患者给药

格隆汇5月5日丨开拓药业-B(9939.HK)高开2.91%，报23港元，总市值89亿港元。开拓药业-B5月4日宣布，于2022年5月2日，公司ALK-1单抗(GT90001)联合Nivolumab治疗晚期肝细胞癌("HCC")的全球多中心II期临床试验(NCT05178043)已完成美国首例患者给药("II期临床试验")。

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.